Navigation Links
ASCRO's Response to NY Times Articles on Radiation Therapy Incidents
Date:2/10/2010

WEXFORD, Pa., Feb. 10 /PRNewswire-USNewswire/ -- Our members deeply regret the needless tragedies outlined in the Times articles and express our sympathy to the families who have lost loved ones and witnessed their suffering.  Our hearts also go out to all others whose lives have been impacted by these tragedies including therapists, physicians and physicists. We feel that, as radiation oncology professionals, we are all, directly or indirectly, responsible for these disastrous treatment errors and we therefore must, in future, take a more active role to assure episodes like these are never repeated. This is why ASCRO is offering a unique solution   which goes to the root of many accidents:  "Provider Status" for clinical radiation oncology physicists.  

Lack of Provider Status = Lack of Authority = Endangered Patients

Board certified medical physicists, even though recognized by the American Board of Medical Specialties (ABMS), were never granted provider status by Congress.  Lacking this distinction, they are, in most cases, excluded from medical staff membership and made to report up a long managerial chain of command.  Although responsible for the radiation treatment process, they are often denied the authority to make decisions based on patient safety and treatment accuracy.

ASCRO, the American Society of Clinical Radiation Oncology, is a professional organization founded in 2009 with the goal of rebuilding and supporting the authority of clinical physicists to prevent the kind of injuries described in the Times article. To this end, ASCRO is committed to provider status and medical staff membership for radiation oncology physicists.  We also support changing reporting structures within treatment facilities so that board certified physicists report at a level commensurate with their educati
'/>"/>

SOURCE American Society of Clinical Radiation Oncology (ASCRO)
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
2. Study identifies key player in the bodys immune response to chronic stress
3. Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911.
4. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
5. Merck & Co., Inc. Response to Todays New York Medicaid Suit
6. Maternal depression and controlling behavior associated with increased stress response in infants
7. Family history of alcoholism affects response to drug used to treat heavy drinking
8. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
9. Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer
10. PET scans can accurately detect a breast tumors response to chemotherapy
11. DNA damage response confers a barrier for viral tumorigenesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... CA (PRWEB) , ... July ... ... recently released a video, “Beachside Nursing Center,” to announce its position as ... five-star ratings. Beachside's administrator and staff members support the CMS rating system, ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zejax is a ... That Increases Training Capability , World renown body weight trainer, Paul Ziachik, ... ), that dramatically increases a person’s training capability. , The American College of ...
(Date:7/30/2015)... ... July 30, 2015 , ... Boston Web ... annual All-Stars Summit. Google Partners is the platform for search marketing agencies to ... support and tools necessary to run successful search marketing campaigns. Google Partners also ...
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... smiles, including lip lowering, gum contouring and surgery, as well as the patented gum ... artistry that has made him popular with many patients from around the world. , ...
(Date:7/30/2015)... ... , ... InventHelp, a leading inventor service company, announces that one ... it easy to apply lotion or medication to a hard-to-reach area. This invention is ... or medication to the back, and provides thorough coverage. The product would prevent the ...
Breaking Medicine News(10 mins):Health News:Beachside Nursing Center Releases New Video 2Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2
... whose conservative dress limits their exposure to sun should be ... serum levels, according to a study published by Henry Ford ... in a small study showed vitamin D levels averaging 8.5 ... to 4 ng/mL for those who wore the hijab, modest ...
... is preliminary and more trials are needed, study says , , ... results from the largest clinical trial of gene therapy for ... and more research must be done before an effective new ... we need to make it better before we launch a ...
... 15 issue of the Journal of Clinical Sleep ... Maintenance of Wakefulness Test (MWT40) is superior to a ... in adults who may be unable to maintain wakefulness ... may not be completely reliable when the strong motivation ...
... 14 A York County jury on Friday awarded $4.4 ... brain injury at birth. The award was against Piedmont Hospital. ... assigned a nurse trainee to monitor Robin Wilson, who arrived ... The nurse misread fetal heart monitoring data showing the baby ...
... potential respiratory effects, study says , , SATURDAY, Feb. 14 ... to women with asthma, U.S. researchers say. , ... in women who did and did not have asthma ... symptoms among the asthmatic women. , Dr. Jonathon A. ...
... Calif., Feb. 13 Lemon Grove Care & ... of Health,s announcement of a "AA" citation issued ... Grove.(Logo: http://www.newscom.com/cgi-bin/prnh/20090213/LA71049LOGO )"We stand by the ... CEO. "We disagree with the Department,s assessment of ...
Cached Medicine News:Health News:Arab-American women need supplement to boost dangerously low vitamin D levels 2Health News:Arab-American women need supplement to boost dangerously low vitamin D levels 3Health News:Gene Therapy Holds Promise for HIV 2Health News:Study finds that using wakefulness tests to detect daytime sleepiness in drivers may be unreliable 2Health News:Study finds that using wakefulness tests to detect daytime sleepiness in drivers may be unreliable 3Health News:Cleaning House May Be Risky for Women With Asthma 2Health News:Lemon Grove Care & Rehabilitation Center Responds to Health Department Announcement 2
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, ... the second Phase III clinical study for Ozenoxacin, ... impetigo.  Medimetriks owns the exclusive U.S. rights to ... trial, conducted at 44 centers with an emphasis ... patients aged 2 months and older with a ...
(Date:7/30/2015)... Global ENT (Ear, Nose, ... USD 23.01 million in 2022, according to a new ... geriatric population, increasing prevalence of ear, nose, and throat ... among target customer base are expected serve this market ... According to estimates published by the WHO, 15% of ...
(Date:7/30/2015)... 2015  NanoSmart Pharmaceuticals, Inc., a private pharmaceutical ... Orphan Drug Designation from the Food and Drug ... uses NanoSmart,s proprietary drug delivery platform. The drug ... treatment of Ewing,s sarcoma, a rare type of ... Drug Designation on the basis of a plausible ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... Nutri-Force Nutrition is proud to announce the ... Miami Lakes, Florida. This new facility was designed ... customers with industry-leading quality and exceptionally efficient manufacturing ... innovative production control processes, the new facility includes ...
... 10 Stryker Corporation (NYSE: SYK ) announced ... held, software technology firm. OtisMed will focus on ... many benefits that surgeons and patients realize from Stryker,s ... OtisMed will operate as part of Stryker,s Orthopaedics Division ...
Cached Medicine Technology:Stryker Announces Agreements To Acquire Assets 2Stryker Announces Agreements To Acquire Assets 3
Immuno-turbidimetric Assay for Protein S Antigen. Suspension of microlatex particles coated with specific antibodies....
Colorimetric Assay of Unfractionated and Low Molecular Weight Heparins by STA© Analyzers. Lyophilized, patent-pending chromogenic substate, CBS 52.44 of ~8.8 moles/vial and bovine factorXa ~2.2 ...
Substrate Plasma for Factor VII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VII has been removed by selective immuno-adsorption....
Substrate Plasma for Factor XI Assay by STA© Analyzers. Freeze-dried human plasma lacking factor XI....
Medicine Products: